TargetSite Therapeutics is a Yale spinout, building an mRNA-targeted therapeutics platform company. Founded on unique insights into mRNA-stabilizing miRNA, we are developing first-in-class molecular therapeutic strategy by inhibiting enhancing miRNA-mRNA interaction with our oligos. Our initial focus is on developing highly specific therapies against validated targets IL-17A and IL23A for the treatment of chronic inflammatory and auto-immune diseases. Our lead candidate is partially de-risked in mouse EAE; autoimmune uveitis and psoriasis are in preclinical stage. Multi cytokines (& non-cytokines) targeting approaches for heterogeneous diseases.